Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
Price:
2.7036 USD
-3.25%
Market Closed
Updated:
Apr 28, 2024
Anebulo Pharmaceuticals Inc
Operating Income
|
Anebulo Pharmaceuticals Inc
Operating Income Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
Operating Income
-$11.8m
|
CAGR 3-Years
-311%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$4.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is Anebulo Pharmaceuticals Inc's Operating Income?
Operating Income
-11.8m
USD
-11.8m
USD
Based on the financial report for Jun 30, 2023, Anebulo Pharmaceuticals Inc's Operating Income amounts to -11.8m USD.
What is Anebulo Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 3Y
-311%
-311%
Over the last year, the Operating Income growth was -72%. The average annual Operating Income growth rates for Anebulo Pharmaceuticals Inc have been -311% over the past three years .
You don't have any saved screeners yet
